U.S. markets open in 2 hours 29 minutes
  • S&P Futures

    4,462.75
    -11.50 (-0.26%)
     
  • Dow Futures

    34,681.00
    -68.00 (-0.20%)
     
  • Nasdaq Futures

    15,487.75
    -30.00 (-0.19%)
     
  • Russell 2000 Futures

    2,219.80
    -8.10 (-0.36%)
     
  • Crude Oil

    72.15
    -0.46 (-0.63%)
     
  • Gold

    1,762.70
    +6.00 (+0.34%)
     
  • Silver

    23.01
    +0.22 (+0.97%)
     
  • EUR/USD

    1.1787
    +0.0015 (+0.13%)
     
  • 10-Yr Bond

    1.3310
    0.0000 (0.00%)
     
  • Vix

    19.54
    +1.36 (+7.48%)
     
  • GBP/USD

    1.3794
    -0.0002 (-0.02%)
     
  • USD/JPY

    109.9840
    +0.2660 (+0.24%)
     
  • BTC-USD

    47,504.68
    -304.10 (-0.64%)
     
  • CMC Crypto 200

    1,206.47
    -26.81 (-2.17%)
     
  • FTSE 100

    7,006.27
    -21.21 (-0.30%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

FDA grants priority review to Pharmacyclics drug

SUNNYVALE, Calif. (AP) -- Pharmacyclics is getting a priority review of its blood cancer treatment by federal regulators.

A priority review shortens a drug evaluation by the Food and Drug Administration from 10 months to six.

The acceptance of the application triggers a $75 million milestone payment to Pharmacyclics from Johnson & Johnson's Janssen unit.

The drug, Ibrutinib, would be Pharmacyclics' first on the market.

Pharmacyclics and Janssen are asking the FDA to approve ibrutinib as a treatment for previously treated cases of mantle cell lymphoma, an aggressive cancer that typically starts in lymph nodes; and chronic lymphocytic leukemia, a slow growing cancer of white blood cells that is the second-most common form of adult leukemia.

The companies say ibrutinib works by shutting down the major growth and survival pathway for cancerous B-cells.

The FDA has deemed the drug a potential breakthrough therapy as a treatment for mantle cell lymphoma, for chronic lymphocytic leukemia in patients with a genetic mutation, and for a type of non-Hodgkin lymphoma.

Shares of Pharmacyclics, based in Sunnyvale, Calif., closed at $111.70 on Wednesday and have climbed about 93 percent so far this year.